CTTC's Calmare therapy effective against pain associated with chemotherapy-induced peripheral neuropathy

Sep 9 2010

Competitive Technologies, Inc. (OTCQB:CTTC) announced today the publication of the detailed results from a study that shows the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy (CIPN) using CTTC's Calmare^® Pain Therapy Treatment. The article published in the Journal of Pain and Symptom Management (www.jpsmjournal.com), detailed the study led by principal investigator, Thomas J. Smith, M.D., Endowed Chair of Palliative Care Research and Medical Director of the Thomas Palliative Care Unit Virginia Commonwealth University's Massey Cancer Center.

Calmare, which treats chronic neuropathic and oncologic pain, received FDA certification for sales in the U.S. in 2009. In June 2009, clinical investigators at the VCU Massey Cancer Center began the first U.S. independent clinical study, to specifically examine the ability of CTTC's Calmare pain therapy treatment to decrease pain associated with CIPN. 

"The Massey Cancer Center team, led by Dr. Smith, was the first independent group in the U.S. to conduct its own evidence-based study using the Calmare pain therapy device to treat CIPN in cancer patients. CIPN is a very debilitating side effect for some 30-40 percent of cancer patients, causing sharp pain in their hands and feet. CIPN affects cancer patients worldwide, including an estimated 4 million cancer patients in the U.S. Calmare pain therapy is the only highly effective treatment for CIPN without the harmful, adverse side effects of opioids," said Johnnie Johnson, Competitive Technologies' interim CEO.

"We are proud of the patient outcomes achieved with this breakthrough treatment in the clinical research study at VCU Massey Cancer Center, a National Cancer Institute-designated center that helps lead our nation's cancer research agenda," said Aris D. Despo, CTTC's Executive VP, Business Development. "We are excited about the investigators' success using Calmare in treating pain. This research confirms our approach to providing a solution to the needs of cancer patients and to improving palliative healthcare globally." 

Calmare is being used to treat international patients in Italy, India, Greece, Bangladesh, and U.S. patients at clinics in Utah, Texas, Massachusetts, New York, Virginia, Florida, Connecticut and Rhode Island.  In addition to treating pain associated with cancer and cancer treatments, Calmare Pain Therapy also successfully treats chronic neuropathic pain resulting from shingles, failed back surgery, phantom limb syndrome, sciatica, spinal stenosis and other maladies.

SOURCE Competitive Technologies, Inc.